- In August 2026, ResMed announced that Carol Burt will become Lead Director in November 2026, the company dismissed KPMG as its auditor and appointed PricewaterhouseCoopers, and it launched a sleep apnea awareness collaboration with 23XI Racing and NASCAR driver Tyler Reddick.
- By pairing a high-profile awareness campaign with board and auditor changes, ResMed is simultaneously reshaping its public profile and its governance framework.
- Next, we’ll examine how the Tyler Reddick sleep apnea awareness partnership could influence ResMed’s long-term sleep health growth narrative.
AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
ResMed Investment Narrative Recap
To own ResMed, you need to believe that long term demand for sleep apnea diagnosis and treatment can support steady growth in devices, masks and software, despite reimbursement and competition risks. Near term, the key catalyst is how effectively ResMed converts greater sleep apnea awareness into more diagnosed and treated patients, while a major risk remains pricing and reimbursement pressure on its core devices. The latest governance and awareness announcements do not appear to materially change those near term drivers.
Among the recent announcements, the Tyler Reddick and NASCAR sleep apnea awareness campaign is most directly tied to that awareness catalyst. By putting a high profile, recently treated patient in front of millions of fans, ResMed is trying to keep sleep health in the public conversation and potentially support testing and therapy adoption, which matters if reimbursement tightens or competing therapies start to pull attention away from CPAP based treatment.
Yet investors should also be aware that if reimbursement pressures intensify and device pricing comes under strain, the story could start to look very different...
Read the full narrative on ResMed (it's free!)
ResMed's narrative projects $6.5 billion revenue and $1.8 billion earnings by 2029.
Uncover how ResMed's forecasts yield a $247.93 fair value, a 5% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming ResMed could lift revenue toward about US$6.8 billion and earnings to roughly US$1.8 billion by 2029, so when you compare that to today’s focus on awareness partnerships and governance changes, you can see how far opinions can stretch and why it is worth exploring several viewpoints before deciding what this new sleep apnea campaign and reimbursement risk might mean for you.
Explore 6 other fair value estimates on ResMed - why the stock might be worth 5% less than the current price!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your ResMed research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free ResMed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ResMed's overall financial health at a glance.
Searching For A Fresh Perspective?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com